FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2591038861> ?p ?o ?g. }

• W2591038861 endingPage "241" @default.
• W2591038861 startingPage "241" @default.
• W2591038861 abstract "241 Background: RRx-001, the first member of a new class of anticancer compounds sourced from the defense industry, is a hypoxia-selective, nitrite reductase-activated prodrug of nitric oxide (NO). The active metabolites selectively enhance oxidative and nitrosative stress in cancer cells through glutathione depletion, ROS formation, and the generation of high local concentrations of NO. The objectives of this Phase 1 dose-escalation trial were to investigate safety, dose-limiting toxicities (DLTs), pharmacodynamics and pharmacokinetics (PK) of RRx-001. Methods: Eligible patients had advanced solid tumor malignancies; ECOG PS 0-2; adequate bone marrow function. In a 3+3 escalation design, RRx-001 was administered intravenously (IV) over 2-3 hours once weekly for 8 weeks to patients with advanced cancer in successive dose-escalating cohorts. PK was collected on days 1 and 50, and tumor blood flow, assessed by CEUS or DCE/DWI-MRI, was performed on days 1 and 8. Tumor response was determined every 8 weeks. Results: To date 12 patients have been dosed across 3 successive cohorts (10, 16.7, and 24.6 mg/m 2 ). Tumor types included pancreas (3), colorectal (5), head and neck (2), melanoma (1), and cholangiocarcinoma (1). No DLTs or treatment-associated SAEs were observed. Transient infusion site pain was reported in 10/12 patients, grade 1 (9/10) or grade 2 (1/10), generally managed by lengthening the infusion duration and using peripheral venous access. No relevant treatment-related changes in laboratory values were observed. Seven patients were evaluable for response, with 1 partial response (parotid tumor). Three patients had stable disease ≥ 2 months (2 pancreas, 1 colorectal with treatment duration 10+ months, exceeding the response to his previous chemo regimen). One pancreas patient with an increase in tumor size due to treatment-related central necrosis was diagnosed with pseudoprogression and remained on study for 4 months. Conclusions: RRx-001, an anticancer agent with a novel structure and mechanism of action, is well tolerated with mild infusion-site pain. PK and PD data will be presented. Escalation is ongoing, but preliminary evidence of anti-tumor activity is promising. Clinical trial information: NCT01359982." @default.
• W2591038861 created "2017-03-03" @default.
• W2591038861 creator A5011901018 @default.
• W2591038861 creator A5016532174 @default.
• W2591038861 creator A5018521707 @default.
• W2591038861 creator A5028976895 @default.
• W2591038861 creator A5043732352 @default.
• W2591038861 creator A5052584121 @default.
• W2591038861 creator A5072308451 @default.
• W2591038861 creator A5090898520 @default.
• W2591038861 date "2013-02-01" @default.
• W2591038861 modified "2023-09-26" @default.
• W2591038861 title "Activity observed in a phase I dose escalation trial of the hypoxia-activated, NO prodrug, RRx001." @default.
• W2591038861 doi "https://doi.org/10.1200/jco.2013.31.4_suppl.241" @default.
• W2591038861 hasPublicationYear "2013" @default.
• W2591038861 type Work @default.
• W2591038861 sameAs 2591038861 @default.
• W2591038861 citedByCount "0" @default.
• W2591038861 crossrefType "journal-article" @default.
• W2591038861 hasAuthorship W2591038861A5011901018 @default.
• W2591038861 hasAuthorship W2591038861A5016532174 @default.
• W2591038861 hasAuthorship W2591038861A5018521707 @default.
• W2591038861 hasAuthorship W2591038861A5028976895 @default.
• W2591038861 hasAuthorship W2591038861A5043732352 @default.
• W2591038861 hasAuthorship W2591038861A5052584121 @default.
• W2591038861 hasAuthorship W2591038861A5072308451 @default.
• W2591038861 hasAuthorship W2591038861A5090898520 @default.
• W2591038861 hasConcept C108215921 @default.
• W2591038861 hasConcept C111113717 @default.
• W2591038861 hasConcept C112705442 @default.
• W2591038861 hasConcept C126322002 @default.
• W2591038861 hasConcept C143998085 @default.
• W2591038861 hasConcept C178790620 @default.
• W2591038861 hasConcept C185592680 @default.
• W2591038861 hasConcept C29730261 @default.
• W2591038861 hasConcept C540031477 @default.
• W2591038861 hasConcept C71924100 @default.
• W2591038861 hasConcept C7836513 @default.
• W2591038861 hasConcept C90924648 @default.
• W2591038861 hasConcept C98274493 @default.
• W2591038861 hasConceptScore W2591038861C108215921 @default.
• W2591038861 hasConceptScore W2591038861C111113717 @default.
• W2591038861 hasConceptScore W2591038861C112705442 @default.
• W2591038861 hasConceptScore W2591038861C126322002 @default.
• W2591038861 hasConceptScore W2591038861C143998085 @default.
• W2591038861 hasConceptScore W2591038861C178790620 @default.
• W2591038861 hasConceptScore W2591038861C185592680 @default.
• W2591038861 hasConceptScore W2591038861C29730261 @default.
• W2591038861 hasConceptScore W2591038861C540031477 @default.
• W2591038861 hasConceptScore W2591038861C71924100 @default.
• W2591038861 hasConceptScore W2591038861C7836513 @default.
• W2591038861 hasConceptScore W2591038861C90924648 @default.
• W2591038861 hasConceptScore W2591038861C98274493 @default.
• W2591038861 hasIssue "4_suppl" @default.
• W2591038861 hasLocation W25910388611 @default.
• W2591038861 hasOpenAccess W2591038861 @default.
• W2591038861 hasPrimaryLocation W25910388611 @default.
• W2591038861 hasRelatedWork W106496334 @default.
• W2591038861 hasRelatedWork W1965330282 @default.
• W2591038861 hasRelatedWork W1987677237 @default.
• W2591038861 hasRelatedWork W2072660971 @default.
• W2591038861 hasRelatedWork W2076942267 @default.
• W2591038861 hasRelatedWork W2110102309 @default.
• W2591038861 hasRelatedWork W272388585 @default.
• W2591038861 hasRelatedWork W3022642844 @default.
• W2591038861 hasRelatedWork W3135583773 @default.
• W2591038861 hasRelatedWork W4293104065 @default.
• W2591038861 hasVolume "31" @default.
• W2591038861 isParatext "false" @default.
• W2591038861 isRetracted "false" @default.
• W2591038861 magId "2591038861" @default.
• W2591038861 workType "article" @default.